Despite a couple of notable ‘firsts’ for European public biotech financing, biotech’s COVID-19 bubble may be about to burst. Virus fears pushed both private and public investors toward biotech, but vaccination successes have changed the sentiment. Now, it seems there are simply too many biotech companies, especially in Europe.
Deutsche Börse publishes BIOTECH Insight
BackgroundEarly December, Deutsche Börse has started BIOTECH Insight, a new information service on the German biotech industry.
US-Greek Venture gets €32m cash injection
Latest NewsUS cell & gene therapy manufacturer Orgenesis Inc. announced that its joint venture with Theracell Advanced Biotechnology SA has received €32m in funding by Enterprise Greece.
The Digital Campus
BackgroundBuilding on a relentless commitment to customer service and innovation, Beckman Coulter Life Sciences debuts a powerful new interactive customer resource with the launch of its Digital Campus. The 3D platform provides greater access to the companys resources regardless of physical location and allows users to control their experience including the chance to get up close and personal with products and experts.
Vaccines burst 2021 biotech bubble
OpinionDespite a couple of notable ‘firsts’ for European public biotech financing, biotech’s COVID-19 bubble may be about to burst. Virus fears pushed both private and public investors toward biotech, but vaccination successes have changed the sentiment. Now, it seems there are simply too many biotech companies, especially in Europe.
Immunovia in search of a new CEO
AppointmentsLund-based Immunovia will need a new CEO, because Patrik Dahlen wants to leave the diagnostics company for personal reasons.
Early-stage ventures fighting AMR wanted!
Latest NewsThe start-up competition @AMR conference supported by INCATE has started. Early-stage ventures fighting drug resistant bacterial infections in the therapeutics or diagnostics area interested to be on stage are invited to apply now!
Quell raises US$156m for Treg cell therapy programme
Latest NewsQuell Therapeutics has raised a whopping US$156m from a prestigious investor group in an oversubscribed Series B financing. With the funds, the British biotech wants to hasten its CAR-Treg cell therapy candidate on its way to the clinic.
Vaccibody – now Nykode – in vaccine deal with Regeneron
Latest NewsVaccibody rebrands as Nykode Therapeutics and teams up with Regeneron in a vaccine deal potentially worth US$925m.
Genoskin appointed CSO
AppointmentsDr Nicolas Gaudenzio has been started at the beginning of November as Chief Scientific Officer of Genoskin.
EC signs prepurchase agreement with Valneva
Latest NewsThe European Commission has inked the pre-purchase agreement over Valnevas inactivated whole virus pandemic vaccine VLA2001 announed in mid-October.